ASH 2022 | Insights into areas of unmet need among patients with hemophilia A
Francis Nissen, MD, PhD, Hoffmann-La Roche Ltd., Basel, Switzerland, discusses unmet needs in patients with hemophilia A (HA), drawing focus on women and infants. Dr Nissen explains that women with HA typically have a much later age of diagnosis and higher prevalence of anemia compared to men. Meanwhile, infants with HA historically have difficulty receiving intravenous prophylaxis treatment – although the availability of subcutaneously-delivered emicizumab may allow for infants to start prophylaxis earlier, as demonstrated by the HAVEN 7 (NCT04431726) trial. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
F. Hoffmann-La Roche Ltd: Current Employment, Current holder of stock options in a privately-held company.
